- Works count
- 488
- Citation count
- 24,063
- H-index
- 64
- i10-index
- 260
Research interests
Publications
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Journal of Clinical Oncology · 2019 · 10.1200/jco.19.01307
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · 10.1016/s0140-6736(17)31827-5
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.48.4410
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.3009
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
Journal of Clinical Oncology · 2006 · 10.1200/jco.2006.06.8429
Current projects
No projects listed.